ATLANTA, April 10, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 22nd Annual Needham Virtual Healthcare Conference. The Company's virtual fireside chat is scheduled to begin at 8:45 a.m. ET on April 18, 2023.
A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stents and stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.
Contacts: | ||
Artivion | Gilmartin Group LLC | |
D. Ashley Lee | Brian Johnston / Lynn Lewis | |
Executive Vice President and | Phone: 332-895-3222 | |
Chief Financial Officer | This email address is being protected from spambots. You need JavaScript enabled to view it. | |
Phone: 770-419-3355 |
Last Trade: | US$31.70 |
Daily Change: | 0.71 2.29 |
Daily Volume: | 394,732 |
Market Cap: | US$1.330B |
January 27, 2025 November 07, 2024 October 10, 2024 August 08, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load